Sign up for Executive Dysfunction, a newsletter that highlights one under-the-radar story each week about how Trump is changing the law—or how the law is pushing back. You’ll also receive updates on the latest from Slate’s Jurisprudence team.

On Friday, the archconservative U.S. Court of Appeals for the 5th Circuit issued a stunning nationwide injunction that directly affects one-fourth of all abortions in the United States. The opinion rejected an Food and Drug Administration regulation allowing people to buy mifepristone, a drug used for medication abortion and miscarriage management, by mail. This ruling applies nationally, even in states that haven’t banned abortion. On Monday, the Supreme Court issued a temporary hold, meaning that mifepristone can still be mailed—for now.

The 5th Circuit’s ruling echoes one from three years ago, also released on a Friday. But this is not déjà vu. Three years ago, President Joe Biden’s FDA appealed the 5th Circuit decision to the Supreme Court to try to maintain access to mifepristone (and succeeded). This time, the Trump administration is complicit in the circuit court’s ruling, while trying to stay under the radar.

To make sense of the administration’s efforts to thread the needle in undermining access to mifepristone, it’s helpful to understand how the FDA regulates it. The agency first approved mifepristone in 2000, after evaluation of rigorous studies demonstrating its effectiveness and safety. The FDA initially required mifepristone to be prescribed in person and taken at a doctor’s office. Over time, and after even more extensive review of safety data, the agency changed some of these restrictions. Most notably, it allowed access via telehealth during the........

© Slate